ArticleCancer2011

A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies.

Evan J Wuthrick et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.